老百姓：业绩稳健增长，中西成药产品持续增长

Investment Rating - The report does not specify a clear investment rating for the company Core Insights - The company reported a steady revenue growth of 1.2% year-on-year, achieving a total revenue of 162.3 billion yuan in the first three quarters of 2024, while the net profit attributable to shareholders decreased by 12.1% to 6.3 billion yuan [1] - The company is implementing the Torch Project to enhance gross profit margins, achieving a gross margin of 33.9% in the first three quarters of 2024, an increase of 1.4 percentage points [2] - The company is focusing on both advantageous provinces and expanding into lower-tier markets, with a total of 15,591 stores, including 10,300 direct-operated and 5,291 franchised stores, adding 2,368 new stores in the first three quarters of 2024 [2] - The new retail segment is growing steadily, with online sales reaching 1.74 billion yuan, a year-on-year increase of 16%, and private domain sales through mini-programs growing by 22.6% [3] Financial Summary - For 2024, the company expects revenues of 235 billion yuan, 270 billion yuan in 2025, and 310 billion yuan in 2026, with net profits of 8.9 billion yuan, 10.0 billion yuan, and 12.6 billion yuan respectively [8] - The company’s revenue growth rates are projected at 4.86% for 2024, 14.77% for 2025, and 14.97% for 2026 [4] - The gross margin is expected to improve from 34.02% in 2024 to 36.14% in 2026 [4] - The earnings per share (EPS) is projected to be 1.22 yuan in 2024, increasing to 1.66 yuan by 2026 [4]